Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.14319 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
Res Pract Thromb Haemost
January 2025
Internal Medicine Department, Hôpital Louis-Mourier, Assistance Publique - Hôpitaux de Paris, Colombes, France.
Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis, venous thromboembolic events (VTEs), and arterial thrombosis. This literature review examines studies reporting the risk of VTEs associated with JAKis in patients with inflammatory diseases.
View Article and Find Full Text PDFEfficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis.
J Clin Med
November 2024
Gastroenterology Unit, Department of Systems Medicine, University "Tor Vergata" of Rome, 00133 Rome, Italy.
Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (); therefore, further information is needed, particularly regarding efficacy and safety. To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in UC. The PubMed and Scopus databases were considered, searching for 'JAK', 'JAK-inhibitor', 'Janus Kinases', 'Tofacitinib', 'Filgotinib', 'Upadacitinib', individually or in combination with 'IBD', 'Ulcerative Colitis', 'safety', 'efficacy', 'study' and 'trial'.
View Article and Find Full Text PDFFracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase.
Drug Saf
February 2025
Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich ETH Zürich, HCI H 407 Vladimir-Prelog-Weg 1-5/10, 8093, Zurich, Switzerland.
Introduction: The Janus kinase (JAK) inhibitors are treatment options for autoimmune diseases. Numerous safety concerns have been raised. The European Medicines Agency updated the product information of tofacitinib to include the risk of fractures-but not for other JAK inhibitors.
View Article and Find Full Text PDFMycophenolate Mofetil, an Inhibitor of Inosine Monophosphate Dehydrogenase, and Tofacitinib, a Janus Kinase Inhibitor, Attenuate Airway Inflammation and Hyperresponsiveness in a Mouse Model of Allergic Asthma.
Molecules
November 2024
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego Street 13, 10-719 Olsztyn, Poland.
Treatment-resistant asthma remains an unresolved clinical problem and a challenge for current medical science. Consequently, there is a growing and urgent need to develop novel or alternative therapeutic options for the treatment of asthma. The research problem raised in this study was to assess and compare mycophenolate mofetil (MMF), an inhibitor of inosine monophosphate dehydrogenase, and tofacitinib (TFB), a Janus kinase inhibitor, for anti-asthmatic properties, and consequently to determine whether these agents may have potential as alternative options for treatment of allergic asthma.
View Article and Find Full Text PDFThe place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease (SJIA-LD): French experience.
Rheumatology (Oxford)
October 2024
Department of Pediatrics, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Objectives: A new form of systemic juvenile idiopathic arthritis (SJIA) with associated lung disease (SJIA-LD) has recently been described. Multiple lines of treatment have failed to yield satisfactory results for this disorder. JAK inhibitors (JAKis) have recently been approved for the treatment of JIA, but clinical evidence of their efficacy in SJIA-LD is still weak.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!